Literature DB >> 17867984

Association of interleukin-1 genetic polymorphisms with the risk of rheumatoid arthritis in Chinese population.

Chong-ge You1, Jian-feng Li, Xiao-dong Xie, Yan Zhu, Pei-qiang Li, Yi-rong Chen.   

Abstract

BACKGROUND: Previous studies suggest that a variable number of tandem repeats polymorphism in the second intron of the interleukin-1 receptor antagonist gene and two single nucleotide polymorphisms at positions -511 and +3954 of the interleukin-1beta (IL-1B) gene are associated with an increased risk of autoimmune diseases. In the present study, we evaluated associations between these genetic factors and an increased risk of rheumatoid arthritis (RA) in a population from Northwest China.
METHODS: A total of 240 patients with RA and 227 healthy controls from Northwest China were investigated using PCR and PCR-restriction fragment length polymorphism. Genotype and allele distributions and haplotype construction were analyzed.
RESULTS: The genotype and allele distributions of IL-1B +3954 and IL-1RN polymorphisms were significantly different in RA patients compared to controls (p<0.001 and p<0.001; p=0.028, p=0.023, respectively). Significant differences were also observed between the RA and control groups for the haplotypes IL-1B -511C/+3954C/IL-1RN *1, IL-1B -511C/+3954T/IL-1RN *1 and IL-1B -511T/+3954T/IL-1RN *1 [p=0.017, odds ratio (OR) 0.721, 95% confidence interval (CI) 0.551-0.944; p=0.030, OR 2.111, 95% CI 1.060-4.204; and p=0.029, OR 2.909, 95% CI 1.066-7.902, respectively].
CONCLUSIONS: These findings suggest that IL-1B +3954 and IL-1RN genetic polymorphisms are associated with a significantly increased risk of RA in this Chinese population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17867984     DOI: 10.1515/CCLM.2007.156

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Association of 86 bp variable number of tandem repeat (VNTR) polymorphism of interleukin-1 receptor antagonist (IL1RN) with susceptibility and clinical activity in rheumatoid arthritis.

Authors:  S Ramírez-Pérez; M Salazar-Páramo; S Pineda-Monjarás; U De la Cruz-Mosso; J Hernández-Bello; G E Martínez-Bonilla; A L Pereira-Suárez; J F Muñoz-Valle
Journal:  Clin Rheumatol       Date:  2017-03-25       Impact factor: 2.980

2.  Pro-inflammatory cytokine response pre-dominates immuno-genetic pathway in development of rheumatoid arthritis.

Authors:  E K Krishna Priya; Lekshmy Srinivas; S Rajesh; Kesavarao Sasikala; Moinak Banerjee
Journal:  Mol Biol Rep       Date:  2020-10-19       Impact factor: 2.316

Review 3.  Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications.

Authors:  Lili Magyari; Dalma Varszegi; Erzsebet Kovesdi; Patricia Sarlos; Bernadett Farago; Andras Javorhazy; Katalin Sumegi; Zsolt Banfai; Bela Melegh
Journal:  World J Orthop       Date:  2014-09-18

4.  Association of the -31C/T functional polymorphism in the interleukin-1beta gene with the intractability of Graves' disease and the proportion of T helper type 17 cells.

Authors:  F Hayashi; M Watanabe; T Nanba; N Inoue; T Akamizu; Y Iwatani
Journal:  Clin Exp Immunol       Date:  2009-09-30       Impact factor: 4.330

5.  TIM family gene polymorphism and susceptibility to rheumatoid arthritis: Systematic review and meta-analysis.

Authors:  Bahman Razi; Samira Esmaeili Reykandeh; Shahab Alizadeh; AliAkbar Amirzargar; Amene Saghazadeh; Nima Rezaei
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

6.  Correlations Between TIMD-4 Gene Variants and the Risk and Clinical Features of Rheumatoid Arthritis in a Chinese Population.

Authors:  Zhicheng Yang; Shuaikun Liu; Li Zhou; Hui Zhang; Nanwei Xu
Journal:  Pharmgenomics Pers Med       Date:  2021-02-09

7.  DNA methyltransferase 3B gene promoter and interleukin-1 receptor antagonist polymorphisms in childhood immune thrombocytopenia.

Authors:  Margarita Pesmatzoglou; Marilena Lourou; George N Goulielmos; Eftichia Stiakaki
Journal:  Clin Dev Immunol       Date:  2012-09-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.